Viruxal Oral and Nasal Spray is a Class I CE marked medical device manufactured by Kerecis hf (the "Device"). A double blind clinical trial will be conducted to evaluate the Device against placebo in COVID-19 positive, symptomatic patients in Iceland. Immediate access to COVID-19 patients is available through a well-organized COVID-19 outpatient follow-up clinic. Up to 128 patients with mild to moderate symptoms of COVID-19 will be recruited (so called "higher end of the low risk group"). These patients will be positive for COVID-19, be symptomatic with upper respiratory symptoms, but without involvement of the entire respiratory system. The patients will be randomized to receive treatment with the Study Device or to receive placebo. 64 patients will be randomized into the Study Device group and 64 patients into the Control group. Patients will administer Study Device or Control for 14 days and will have their symptoms recorded until no further symptoms are reported, up to a maximum of 28 days follow-up.

Inclusion Criteria:

• ≥18 years of age
• Positive for SARS-CoV-2 infection
• Has symptoms of upper respiratory infection
• Willing to participate in the clinical trial and gives consent
• Is not pregnant, nor actively trying to conceive a child.

Exclusion Criteria:

• Under 18 years of age
• Negative for SARS-CoV-2 infection
• Severe symptoms of infection
• Symptoms involving the entire respiratory system, including Pneumonia
• Requires hospitalisation prior to study start
• Asymptomatic
• Pregnant or actively trying to conceive a child
• Other comorbidities that would prevent administration of the device
• Requirement to take regular medications administered by inhalation, or via the naso- and oropharyngeal route
• Patients with known allergies to Neem or Hypericum oil
• Patients with asthma